Patents Examined by Lynn A. Bristol
  • Human IgG1 derived antibody with pro-apoptotic activity
    Patent number: 10669328
    Abstract: A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1?1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1?1 domain by the CH1 domain from a human IgG2 (CH1?2), IgG3 (CH1?3) or IgG4 (CH1?4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (?)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: June 2, 2020
    Assignee: OGD2 PHARMA
    Inventors: Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • Antigen-binding constructs that bind to and inhibit catalase and/or superoxide dismutase as well as pharmaceutical compositions containing them for tumor therapy
    Patent number: 10669350
    Abstract: The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 2, 2020
    Inventors: Georg Bauer, Manfred Motz
  • Anti-Ly6E antibodies and immunoconjugates and methods of use
    Patent number: 10653792
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of treating cancer using the same.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Chang, Chie Sakanaka
  • Multi-chain polypeptide-containing tri-specific binding molecules
    Patent number: 10647768
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 12, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Anti-TIM-3 antibodies and methods of use thereof
    Patent number: 10639368
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
    Patent number: 10633440
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Ezio Bonvini, Paul A. Moore, Jonathan C. Li, Leslie S. Johnson, Kalpana Shah
  • Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
    Patent number: 10633451
    Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 28, 2020
    Assignees: Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität München
    Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
  • Multispecific antibodies
    Patent number: 10633457
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
  • Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
    Patent number: 10633443
    Abstract: CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: April 28, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
    Patent number: 10626184
    Abstract: In various embodiments the invention provides anti-mucin-like protein (MLP) monoclonal antibodies, compositions and methods for detecting MLP as a biomarker for mucin-secreting type of cancer such as ovarian or pancreatic cancer.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 21, 2020
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Hans-Wilhelm Schwaeble, Gregory A. Demopulos
  • High affinity T cell receptor and use thereof
    Patent number: 10626159
    Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding the same, a T cell expressing the TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing the tumor-associated antigen.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 21, 2020
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Anti-HER2 glycoantibodies and uses thereof
    Patent number: 10618973
    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 14, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Human monoclonal anti-PD-L1 antibodies and methods of use
    Patent number: 10604581
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 31, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Antibodies targeting G-protein coupled receptor and methods of use
    Patent number: 10590196
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 17, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Modified cell expansion and uses thereof
    Patent number: 10561686
    Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: February 18, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Anti-ANG2 antibodies and methods of use
    Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Anti SEZ6 antibodies and methods of use
    Patent number: 10533051
    Abstract: Provided are novel seizure related 6 (SEZ6) modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 14, 2020
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Non-immunogenic single domain antibodies
    Patent number: 10526397
    Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 7, 2020
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Anti-PD-L1 antibodies
    Patent number: 10517949
    Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: December 31, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo